Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer

  title={Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer},
  author={Aditya Bardia and Ingrid A. Mayer and Linda T Vahdat and Sara M. Tolaney and Steven J. Isakoff and Jennifer R. Diamond and Joyce O’Shaughnessy and Rebecca L. Moroose and Alessandro D. Santin and Vandana G. Abramson and Nikita C. Shah and Hope S. Rugo and David M. Goldenberg and Alaa Sweidan and R. Iannone and Sarah A. Washkowitz and Robert M Sharkey and William A. Wegener and Kevin Kalinsky},
  journal={The New England Journal of Medicine},
BACKGROUND Standard chemotherapy is associated with low response rates and short progression‐free survival among patients with pretreated metastatic triple‐negative breast cancer. Sacituzumab govitecan‐hziy is an antibody–drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell‐surface antigen 2 (Trop‐2), with SN‐38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan‐hziy enables delivery of high concentrations of SN‐38… 

Figures and Tables from this paper

Sacituzumab Govitecan For Metastatic Triple Negative Breast Cancer: Clinical Overview And Management Of Potential Toxicities.

The clinical development of the drug, the AE profile and recommendations regarding AE management to help optimize therapy with sacituzumab govitecan are reviewed.

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative breast cancer.

Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer

The FDA has granted full regulatory approval for sacituzumab govitecan, a monoclonal antibody targeted at Trop-2 and contains the active metabolite of irinotecan, SN-38, as a cytotoxic side moiety, for the treatment of patients with metastatic triple-negative breast cancer.

Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer

The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer, with the most common adverse events being nausea, neutropenia, and diarrhea.

Role of sacituzumab govitecan in solid tumors

Sacituzumab has showed significantly improved Health-related quality of life (HRQoL) in addition to prolonged progression free survival and Over all survival and maintaining a good safety profile, and is a significant advancement made in cancer therapy.

Tackling metastatic triple-negative breast cancer with sacituzumab govitecan

Sacituzumab govitecan has promising survival benefits in patients with previously treated mTNBC based on data from the ASCENT trial, and is being evaluated in HR-positive breast cancers.

Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.

Patients with metastatic triple-negative breast cancer (mTNBC) that has progressed on first-line therapy have a poor prognosis with limited therapeutic options. Sacituzumab govitecan (SG) is a novel

Sacituzumab Govitecan-hziy in Breast Cancer

Sacituzumab govitecan-hziy (SG), the anti-Trop-2 antibody-drug conjugate, resulted in a significant survival benefit over chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC).

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

This article summarizes the FDA review process and data supporting the approval of sacituzumab govitecan and describes the most common adverse reactions occurring in patients.

A closer look at sacituzumab govitecan-hziy.

  • A. Bardia
  • Medicine
    Clinical advances in hematology & oncology : H&O
  • 2020
This agent delivers high doses of the antineoplastic drug SN-38 to cancer cells, while relatively sparing noncancerous cells, and should be considered a new standard of care in patients with pretreated, metastatic triple-negative breast cancer.



Trastuzumab emtansine for HER2-positive advanced breast cancer.

T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

  • A. BardiaI. Mayer L. Vahdat
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017
Sacituzumab govitecan was well tolerated and induced early and durable responses in heavily pretreated patients with metastatic TNBC, and Trop-2 warrants further research.

Palbociclib and Letrozole in Advanced Breast Cancer.

Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with let rozole alone, although the rates of myelotoxic effects were higher with palbokiclib-letrozoles.

FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma

The benefits of the observed ORR with prolonged duration of responses outweighed the risks of immune-mediated adverse reactions in this life-threatening disease and represented an improvement over available therapy.

Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer

Ixabepilone shows notable antitumor activity in patients with triple-negative breast cancer when used in a variety of settings and results in an approximately twofold increase in median PFS for triple- negative patients versus capecitabine alone and responses to ixabepILone in triple- Negative disease are comparable to those seen in patientsWith non-triple-negative tumors.

Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

This report further examines the pharmacokinetics and safety of multiple cycles of IMMU‐132 at doses of 8 or 10 mg/kg in patients with diverse advanced epithelial cancers.

Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies

This review summarizes the clinical efficacy, perspectives and future challenges of using new treatment options for metastatic TNBC, such as poly‐ADP‐ribose‐polymerase inhibitors, antiandrogen therapies and immune checkpoint inhibitors (antiprogrammed death receptor‐1/PD‐L1 monoclonal antibodies).

A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer

The standard systemic and future treatment options in mTNBC are evaluated, including targeted therapy and immunotherapy, and select synergistic combinations can produce faster and more significant response rates compared with monotherapy.

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

This phase I trial evaluated Sacituzumab govitecan as a potential therapeutic for pretreated patients with a variety of metastatic solid cancers and found it had acceptable toxicity and encouraging therapeutic activity in patients with difficult-to-treat cancers.

Biology and Management of Patients With Triple-Negative Breast Cancer.

Clinical features, current treatment paradigms, the role of germline testing, and platinum agents in TNBC are reviewed, and the molecular diversity of this unique subtype is discussed.